GeneTherapyLive’s Weekly Rewind – January 28, 2022

Article

Review top news and interview highlights from the week ending January 28, 2022.

Welcome to GeneTherapyLive’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.

1. HLA LOH Prevalent in GI Cancers, Identifies Future Study Participants

Investigators have identified the prevalence of Human Leukocyte Antigen Loss of Heterozygosity (HLA LOH) in gastrointestinal tumors as part of the BASECAMP-1 study (NCT04981119) for future use of Tmod CAR T-cell therapy.

2. Omidubicel BLA Submission for Hematologic Malignancies Expected First Half of 2022

Gamida Cell is planning to complete their BLA for omidubicel (NiCord), a cell therapy for bone marrow transplant in patients with hematologic malignancies, in the first half of 2022 following positive Type B meeting correspondence from the FDA.

3. Improving Outcomes in Hemophilia WithFitusiran: Guy Young, MD

The director of the hemostasis and thrombosis program at Children’s Hospital Los Angeles discussed advantages of the siRNA therapeutic. He discussed unmet needs in hemophilia B and the decent population included in the ATLAS-INH study.

4. Around the Helix: Gene and Cell Therapy Company Updates - January 26, 2022

GeneTherapyLive’s Around the Helix is your chance to catch up with the latest news in gene and cell therapies, including partnerships, pipeline updates, and more.

5. DLBC Lymphoma CAR T Therapy Granted RMAT and Fast Track Designations

The FDA has granted regenerative medicine advanced therapy and fast track designation to C-CAR039 for patients with relapsed or refractory diffuse large B-cell lymphoma.

Related Videos
Maria Escolar, MD, the chief medical officer of Forge Biologics
Leigh Ramos-Platt, MD, on Allowing Access and Ensuring Preparation for Gene Therapies
John Murphy, PhD, the chief scientific officer of Arbor Biotechnologies
Erika Fullwood Augustine, MD, MS, the associate chief science officer of the Kennedy Krieger Institute
Maria Escolar, MD, the chief medical officer of Forge Biologics
Casey Maguire, PhD, associate professor of neurology and associate investigator of neurology, Harvard Medical School
Evan Weber, PhD, an assistant professor of pediatrics at Children's Hospital of Philadelphia
Shankar Ramaswamy, MD, the cofounder, chairman, and CEO of Kriya Therapeutics
Kevin Campbell, PhD, a Howard Hughes Investigator at the University of Iowa
Debora Mazzetti, MS, on Multitargeting MicroRNA in Glioblastoma
© 2024 MJH Life Sciences

All rights reserved.